Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary safety objective of this study is to evaluate the safety of vernakalant injection in subjects with recent onset (AF > 3 hours to less than or equal to 7 days), symptomatic atrial fibrillation, and no evidence or history of congestive heart failure (CHF). The primary efficacy objective is to demonstrate the efficacy of vernakalant injection in converting atrial fibrillation (AF) to sinus rhythm (SR) in subjects with recent onset (AF > 3h to less than or equal to 7 days), symptomatic atrial fibrillation and no evidence or history of congestive heart failure (CHF).
Inclusion criteria
- Recent Onset Symptomatic Atrial Fibrillation